CY1113148T1 - Χρηση υποκατεστημενων παραγωγων πυρανονικου οξεος για τη θεραπευτικη αντιμετωπιση του μεταβολικου συνδρομου - Google Patents
Χρηση υποκατεστημενων παραγωγων πυρανονικου οξεος για τη θεραπευτικη αντιμετωπιση του μεταβολικου συνδρομουInfo
- Publication number
- CY1113148T1 CY1113148T1 CY20121100882T CY121100882T CY1113148T1 CY 1113148 T1 CY1113148 T1 CY 1113148T1 CY 20121100882 T CY20121100882 T CY 20121100882T CY 121100882 T CY121100882 T CY 121100882T CY 1113148 T1 CY1113148 T1 CY 1113148T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pyranonic
- substituted
- therapeutic
- syndrome treatment
- acid producers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
Abstract
Η εφεύρεση αφορά στη χρήση υποκατεστημένων παραγώγων πυρανονικού οξέος καθώς και των φυσιολογικά ανεκτών αλάτων τους για την παρασκευή φαρμάκων για τη θεραπευτική αντιμετώπιση του μεταβολικού συνδρόμου. Περιγράφεται η χρήση των ενώσεων του τύπου (I), όπου τα υπόλοιπα έχουν τις δεδομένες σημασίες, καθώς και των φυσιολογικά ανεκτών αλάτων τους για την παρασκευή φαρμάκων για τη θεραπευτική αντιμετώπιση του μεταβολικού συνδρόμου.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102007002260A DE102007002260A1 (de) | 2007-01-16 | 2007-01-16 | Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms |
EP08700981A EP2120923B1 (de) | 2007-01-16 | 2008-01-04 | Verwendung von substituierten pyranonsäurederivaten zur behandlung des metabolischen syndroms |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1113148T1 true CY1113148T1 (el) | 2016-04-13 |
Family
ID=39232744
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20121100882T CY1113148T1 (el) | 2007-01-16 | 2012-09-27 | Χρηση υποκατεστημενων παραγωγων πυρανονικου οξεος για τη θεραπευτικη αντιμετωπιση του μεταβολικου συνδρομου |
Country Status (31)
Country | Link |
---|---|
US (1) | US8748483B2 (el) |
EP (1) | EP2120923B1 (el) |
JP (1) | JP2010515765A (el) |
KR (1) | KR20090110834A (el) |
CN (1) | CN101600427A (el) |
AR (1) | AR064899A1 (el) |
AU (1) | AU2008207170A1 (el) |
BR (1) | BRPI0806661A2 (el) |
CA (1) | CA2675442A1 (el) |
CL (1) | CL2008000110A1 (el) |
CR (1) | CR10850A (el) |
CY (1) | CY1113148T1 (el) |
DE (1) | DE102007002260A1 (el) |
DK (1) | DK2120923T3 (el) |
DO (1) | DOP2009000177A (el) |
EC (1) | ECSP099518A (el) |
ES (1) | ES2390513T3 (el) |
HR (1) | HRP20120763T1 (el) |
IL (1) | IL199829A0 (el) |
MA (1) | MA31094B1 (el) |
MX (1) | MX2009006913A (el) |
PE (1) | PE20081700A1 (el) |
PL (1) | PL2120923T3 (el) |
PT (1) | PT2120923E (el) |
RS (1) | RS52494B (el) |
RU (1) | RU2009131058A (el) |
SI (1) | SI2120923T1 (el) |
TN (1) | TN2009000275A1 (el) |
TW (1) | TW200836716A (el) |
UY (1) | UY30871A1 (el) |
WO (1) | WO2008086949A1 (el) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US20150306002A1 (en) * | 2012-12-13 | 2015-10-29 | Merck Patent Gmbh | 3-hydroxy-4-oxo-4h-pyran- or 3-hydroxy-4-oxo-1,4-dihydropyridine derivatives as protein-adhesive active substances |
JP6338276B2 (ja) * | 2014-07-10 | 2018-06-06 | 学校法人神奈川大学 | 抗癌剤 |
AU2021324839B2 (en) * | 2020-08-12 | 2024-02-29 | Spruce Biosciences, Inc. | Methods and compositions for treating polycystic ovary syndrome |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3152148A (en) | 1963-01-03 | 1964-10-06 | Dow Chemical Co | Preparation of comenic and pyromeconic acids |
DE2966702D1 (en) | 1978-06-26 | 1984-03-29 | Measurex Corp | Method and apparatus for measuring gas, including standardisation |
JPS59125644A (ja) | 1982-12-29 | 1984-07-20 | Fujitsu Ltd | 半導体装置 |
US4603144A (en) | 1984-08-16 | 1986-07-29 | G. D. Searle & Co. | Kojic acid ether-ester derivatives |
GB8615041D0 (en) * | 1986-06-20 | 1986-07-23 | Silver J | Pharmaceutical compositions |
DE3728602A1 (de) | 1987-08-27 | 1989-03-09 | Bayer Ag | Faserverstaerktes polyphenylensulfid |
DE3728924A1 (de) | 1987-08-29 | 1989-03-09 | Bayer Ag | Flammwidrige, thermoplastische formmassen auf basis von polycarbonat, polyalkylenterephthalat, pfropfcopolymerisat, fluoriertem polyolefin und phosphorverbindung |
DE3729586A1 (de) | 1987-09-04 | 1989-03-16 | Ant Nachrichtentech | Verfahren zum ausgleichen von durch den doppler-effekt hervorgerufenen laufzeit-verschiebungen der bursts in einem tdma-rahmen sowie anordnung |
CA2007414C (en) | 1989-04-26 | 1994-10-25 | Clayton James Bennett Iii | Method for manipulating elements within a structured document using active intent interpretations |
FR2663336B1 (fr) | 1990-06-18 | 1992-09-04 | Adir | Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
JPH06271500A (ja) * | 1993-03-23 | 1994-09-27 | Noguchi Kenkyusho | コマン酸の製造法 |
DE19530298C2 (de) * | 1995-08-17 | 1999-07-22 | Woerwag Pharma Gmbh | Verwendung von Orotsäure zur Prävention und Therapie des metabolischen Syndroms |
BR9707003A (pt) | 1996-01-17 | 1999-07-20 | Novo Nordisk As | Composto processos para preparar o mesmo para tratamento ou de prevenção de doenças do sistema endócrino e para a manufatura de medicamento coposção farmacêutica e utilização de um composto |
UA51716C2 (uk) | 1996-07-08 | 2002-12-16 | Авентіс Фармасьютікалз Продактс Інк. | Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування |
CA2468374C (en) | 1996-08-30 | 2010-12-21 | Novo-Nordisk A/S | Glp-1 derivatives |
CN1190434C (zh) | 1996-12-31 | 2005-02-23 | 雷迪实验室有限公司 | 新的杂环化合物、其制备方法和含有它们的药物组合物及其在治疗糖尿病和相关疾病中的应用 |
DE19726167B4 (de) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
BR9810592A (pt) | 1997-07-16 | 2000-09-12 | Novo Nordisk As | Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto |
CO4970713A1 (es) | 1997-09-19 | 2000-11-07 | Sanofi Synthelabo | Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen |
US6221897B1 (en) | 1998-06-10 | 2001-04-24 | Aventis Pharma Deutschland Gmbh | Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use |
DE19845405C2 (de) | 1998-10-02 | 2000-07-13 | Aventis Pharma Gmbh | Arylsubstituierte Propanolaminderivate und deren Verwendung |
GB9900416D0 (en) | 1999-01-08 | 1999-02-24 | Alizyme Therapeutics Ltd | Inhibitors |
WO2000063208A1 (en) | 1999-04-16 | 2000-10-26 | Novo Nordisk A/S | Substituted imidazoles, their preparation and use |
SK15522001A3 (sk) | 1999-04-28 | 2002-06-04 | Aventis Pharma Deutschland Gmbh | Deriváty kyselín s tromi arylovými zvyškami ako ligandy receptorov PPAR a farmaceutické kompozície, ktoré ich obsahujú |
ES2287016T3 (es) | 1999-04-28 | 2007-12-16 | Sanofi-Aventis Deutschland Gmbh | Derivados de diaril-acido como ligandos del receptor ppar. |
CA2371271A1 (en) | 1999-04-30 | 2000-11-09 | Neurogen Corporation | 9h-pyrimido[4,5-b]indole derivatives: crf1 specific ligands |
GB9911863D0 (en) | 1999-05-21 | 1999-07-21 | Knoll Ag | Therapeutic agents |
US6399640B1 (en) | 1999-06-18 | 2002-06-04 | Merck & Co., Inc. | Arylthiazolidinedione and aryloxazolidinedione derivatives |
JP2003506365A (ja) | 1999-07-29 | 2003-02-18 | イーライ・リリー・アンド・カンパニー | ベンゾフリルピペラジンおよびベンゾフリルホモピペラジン:セロトニンアゴニスト |
PL353367A1 (en) | 1999-09-01 | 2003-11-17 | Aventis Pharma Deutschland Gmbh | Sulfonyl carboxamide derivatives, method for their production and their use as medicaments |
CN1430603A (zh) | 2000-04-28 | 2003-07-16 | 旭化成株式会社 | 新型双环化合物 |
DE60115227T2 (de) | 2000-05-11 | 2006-08-24 | Bristol-Myers Squibb Co. | Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga |
EP1289526A4 (en) | 2000-05-30 | 2005-03-16 | Merck & Co Inc | MELANOCORTIN RECEPTOR AGONISTS |
DE10033353A1 (de) | 2000-07-08 | 2002-01-24 | Aventis Pharma Gmbh | Breit einsetzbares Verfahren zur Identifizierung von Modulatoren von G-Protein gekoppelten Rezeptoren |
FR2814678B1 (fr) | 2000-10-04 | 2002-12-20 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite |
IL156552A0 (en) | 2000-12-21 | 2004-01-04 | Aventis Pharma Gmbh | Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use |
UA76773C2 (uk) | 2001-08-31 | 2006-09-15 | Санофі-Авентіс Дойчланд Гмбх | Діарилциклоалкільні похідні, спосіб їх одержання і їх застосування як ppar-активаторів |
US6552073B1 (en) | 2002-03-01 | 2003-04-22 | Exonhit Therapeutics Sa | Compounds and methods of treating cell proliferative diseases |
DE10227507A1 (de) | 2002-06-19 | 2004-01-08 | Aventis Pharma Deutschland Gmbh | Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
DE10227506A1 (de) | 2002-06-19 | 2004-01-08 | Aventis Pharma Deutschland Gmbh | Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
DE10227508A1 (de) | 2002-06-19 | 2004-01-08 | Aventis Pharma Deutschland Gmbh | Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
DE10307004B3 (de) | 2003-02-19 | 2004-08-05 | Siemens Ag | Verfahren zur Steuerung einer Brennkraftmaschine mit einer Lambda-Regelung |
-
2007
- 2007-01-16 DE DE102007002260A patent/DE102007002260A1/de not_active Withdrawn
-
2008
- 2008-01-04 JP JP2009545849A patent/JP2010515765A/ja not_active Withdrawn
- 2008-01-04 ES ES08700981T patent/ES2390513T3/es active Active
- 2008-01-04 AU AU2008207170A patent/AU2008207170A1/en not_active Abandoned
- 2008-01-04 RS RS20120437A patent/RS52494B/en unknown
- 2008-01-04 KR KR1020097014783A patent/KR20090110834A/ko not_active Application Discontinuation
- 2008-01-04 CA CA002675442A patent/CA2675442A1/en not_active Abandoned
- 2008-01-04 DK DK08700981.7T patent/DK2120923T3/da active
- 2008-01-04 RU RU2009131058/15A patent/RU2009131058A/ru unknown
- 2008-01-04 CN CNA2008800023932A patent/CN101600427A/zh active Pending
- 2008-01-04 MX MX2009006913A patent/MX2009006913A/es not_active Application Discontinuation
- 2008-01-04 PT PT08700981T patent/PT2120923E/pt unknown
- 2008-01-04 PL PL08700981T patent/PL2120923T3/pl unknown
- 2008-01-04 BR BRPI0806661-2A patent/BRPI0806661A2/pt not_active IP Right Cessation
- 2008-01-04 WO PCT/EP2008/000029 patent/WO2008086949A1/de active Application Filing
- 2008-01-04 EP EP08700981A patent/EP2120923B1/de active Active
- 2008-01-04 SI SI200830757T patent/SI2120923T1/sl unknown
- 2008-01-14 PE PE2008000138A patent/PE20081700A1/es not_active Application Discontinuation
- 2008-01-14 TW TW097101284A patent/TW200836716A/zh unknown
- 2008-01-14 UY UY30871A patent/UY30871A1/es not_active Application Discontinuation
- 2008-01-14 AR ARP080100165A patent/AR064899A1/es not_active Application Discontinuation
- 2008-01-15 CL CL200800110A patent/CL2008000110A1/es unknown
-
2009
- 2009-06-09 CR CR10850A patent/CR10850A/es not_active Application Discontinuation
- 2009-06-26 TN TNP2009000275A patent/TN2009000275A1/fr unknown
- 2009-07-13 DO DO2009000177A patent/DOP2009000177A/es unknown
- 2009-07-13 IL IL199829A patent/IL199829A0/en unknown
- 2009-07-14 MA MA32090A patent/MA31094B1/fr unknown
- 2009-07-15 EC EC2009009518A patent/ECSP099518A/es unknown
- 2009-07-16 US US12/504,198 patent/US8748483B2/en not_active Expired - Fee Related
-
2012
- 2012-09-26 HR HRP20120763AT patent/HRP20120763T1/hr unknown
- 2012-09-27 CY CY20121100882T patent/CY1113148T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
TN2009000275A1 (en) | 2010-10-18 |
PL2120923T3 (pl) | 2012-12-31 |
DOP2009000177A (es) | 2009-08-15 |
PE20081700A1 (es) | 2009-01-08 |
CL2008000110A1 (es) | 2008-05-16 |
IL199829A0 (en) | 2010-04-15 |
DK2120923T3 (da) | 2012-10-29 |
MX2009006913A (es) | 2009-08-12 |
EP2120923A1 (de) | 2009-11-25 |
US8748483B2 (en) | 2014-06-10 |
AR064899A1 (es) | 2009-05-06 |
KR20090110834A (ko) | 2009-10-22 |
DE102007002260A1 (de) | 2008-07-31 |
RS52494B (en) | 2013-02-28 |
US20100144862A1 (en) | 2010-06-10 |
JP2010515765A (ja) | 2010-05-13 |
CR10850A (es) | 2009-10-16 |
CA2675442A1 (en) | 2008-07-24 |
CN101600427A (zh) | 2009-12-09 |
PT2120923E (pt) | 2012-08-31 |
BRPI0806661A2 (pt) | 2011-09-06 |
EP2120923B1 (de) | 2012-07-18 |
SI2120923T1 (sl) | 2012-10-30 |
UY30871A1 (es) | 2008-09-02 |
TW200836716A (en) | 2008-09-16 |
WO2008086949A1 (de) | 2008-07-24 |
HRP20120763T1 (hr) | 2012-10-31 |
AU2008207170A1 (en) | 2008-07-24 |
ES2390513T3 (es) | 2012-11-13 |
ECSP099518A (es) | 2009-08-28 |
RU2009131058A (ru) | 2011-02-27 |
MA31094B1 (fr) | 2010-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1113148T1 (el) | Χρηση υποκατεστημενων παραγωγων πυρανονικου οξεος για τη θεραπευτικη αντιμετωπιση του μεταβολικου συνδρομου | |
CY1117330T1 (el) | Βενζοδιοξινυλ υποκατεστημενα παραγωγα ινδαζολιου | |
CY1118678T1 (el) | Παραγωγα καρβοξαμιδιου χλωρο-πυραζινης χρησιμα για την θεραπευτικη αντιμετωπιση ασθενειων που ευνοουνται απο την ανεπαρκη ενυδατωση του βλεννογονου | |
CY1113177T1 (el) | Φαινυλαμινο-βενζοξαζολ-υποκατεστημενα καρβοξυλικα οξεα, μεθοδος για την παρασκευη τους και η χρηση τους ως φαρμακων | |
EA201390401A1 (ru) | ПИРАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ENaC БЛОКАТОРОВ | |
CY1115199T1 (el) | Κυτταροτοξικοι παραγοντες που περιεχουν νεα παραγωγα τομαϋμυκινης και η θεραπευτικη τους χρηση | |
CY1112831T1 (el) | Παραγωγα αζαβιρηενυlαμινοβενζοιc acid σαν παραγοντες καταστολης dhodh | |
EA201491060A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
CY1116057T1 (el) | Παραγωγα κιναζολιν-4(3η)-ονης που χρησιμοποιουνται ως αναστολεις κινασης ρι3 | |
EA201100503A1 (ru) | Глюкозидные производные и их применения | |
UY32174A (es) | Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones | |
EA201390381A1 (ru) | Триазиноксадиазолы | |
CY1112921T1 (el) | Ενεργοποιητες γλυκοκινασης πυρρολιδινονης | |
CY1110115T1 (el) | Παραγωγα ακετυλενυλο-πυραζολο-πυριμιδινης ως mglur2 ανταγωνιστες | |
ECSP088747A (es) | Pirazoles como inhibidores de la 11-beta-hsd1 | |
MX2010010647A (es) | Proceso para preparar formulaciones de dabigatran para administracion oral. | |
EA201200318A1 (ru) | Гетероциклические оксимы | |
CY1112115T1 (el) | Παραγωγα φαινοξυοξικου οξεος χρησιμα για τη θεραπευτικη αντιμετωπιση ασθενειων του αναπνευστικου | |
EA201200471A1 (ru) | Простые эфирные производные бициклических гетероарилов | |
EA201391525A1 (ru) | Гликозидные производные и их применение для лечения диабета | |
CY1115590T1 (el) | Σουλφοξιμινυποκατεστημενα παραγωγα ανιλινοπυριμιδινης ως cdk-αναστολεις, η παραγωγη αυτων και η χρηση αυτων ως φαρμακευτικα μεσα | |
EA201792072A3 (ru) | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения | |
EA201490630A1 (ru) | 6-замещенные 3-(хинолин-6-илтио)[1,2,4]триазоло[4,3-a]пиридины в качестве ингибиторов c-met тирозинкиназы | |
CY1113240T1 (el) | Αλατα ενωσεων αναστολεα hiv | |
CY1111574T1 (el) | Παραγωγα βουτανοϊκου οξεος, διαδικασιες για την παρασκευη τους, φαρμακευτικες συνθεσεις που τα περιλαμβανουν και θεραπευτικες εφαρμογες αυτων |